Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

Inclusion Criteria: * Age 70 years or older, regardless of sex. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed non-small cell lung cancer, clinical stage IIA-IIIB according to the 8th edition of the AJCC staging system. * No evidence of distant metastasis and considered suitable for radical lung cancer surgery. * The primary lung lesion is suitable for stereotactic body radiotherapy. * No sensitizing driver alterations in EGFR, ALK, ROS1, or other tested actionable genes. * Adequate major organ function, including all of the following: * Absolute neutrophil count at least 1.5 × 10\^9/L, platelet count at least 100 × 10\^9/L, and hemoglobin at least 9 g/dL. * Total bilirubin no more than 1.5 × the upper limit of normal; alanine aminotransferase and aspartate aminotransferase no more than 2.5 × the upper limit of normal. * Serum creatinine no more than 1.5 × the upper limit of normal or creatinine clearance at least 60 mL/min. * Urine protein less than 1+; if urine protein is 1+, 24-hour urine protein must be less than 500 mg. * Blood glucose within the normal range or stable glycemic control in participants with diabetes. * Baseline forced expiratory volume in 1 second (FEV1) at least 2 L; if FEV1 is less than 2 L, the predicted postoperative FEV1 must be greater than 800 mL as assessed by a thoracic surgeon. * No myocardial infarction within the previous year, no unstable angina, no symptomatic severe arrhythmia, and no cardiac insufficiency. * The participant has been fully informed and voluntarily provides written informed consent. Exclusion Criteria: * Prior lobectomy, thoracic radiotherapy, or systemic antitumor therapy. * Another concurrent malignancy or a history of another malignancy cured less than 5 years before enrollment, except adequately treated cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin. * Active autoimmune disease or a history of autoimmune disease requiring systemic immunosuppressive treatment. * Active infection requiring systemic treatment, active tuberculosis, human immunodeficiency virus infection, active hepatitis B or hepatitis C, active syphilis, or another active transmissible infection specified by the protocol. * Severe cardiac, hepatic, renal, or metabolic disease that precludes surgery or study treatment. * History of interstitial lung disease or drug-induced pneumonitis, or imaging evidence of active interstitial lung disease. * Uncontrolled large pleural effusion or pericardial effusion. * Major surgery, severe trauma, or treatment with another investigational drug within 4 weeks before enrollment. * Recent receipt of an anticancer vaccine or live vaccine. * Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study or may interfere with interpretation of the study results.